California Healthline April 15, 2021
Harris Meyer

Chuck Peterson of Omaha, Nebraska, recently experienced a swollen, painful knuckle caused by arthritis. He got a prescription for colchicine.

Doctors have used the drug for treating gout and other rheumatic conditions for well over two centuries.

When Peterson went to the pharmacy, he was shocked to discover that a two-month supply of 120 pills, distributed by Par Pharmaceutical, would cost him $225 out-of-pocket on his Medicare Part D drug plan. Taking it for an additional three months, as his rheumatologist wanted him to do, would cost him nearly $600 under his drug plan.

A dozen years ago, the drug cost about a dime per pill.

“My reaction was ‘goodness gracious,’ or maybe something I couldn’t say in polite company,”...

Today's Sponsors

Teladoc Health
Premier
TripleTree

Today's Sponsors

SalesSparx
Canton & Company

Today's Sponsor

HLTH

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
NIH to test repurposing up to 7 drugs to treat COVID-19 symptoms at home
Decentralized Clinical Trials: Surviving & Thriving in the Clinical Research World of COVID-19
To Improve Competition In Generic Drug Markets, The FDA Should Discount User Fees For Small Players
Designing better antibody drugs with artificial intelligence
Why Pharma Companies Must Stop Saying ‘Digital Transformation’